Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 30Terminated 13Unknown 6Active not recruiting 6Withdrawn 4Recruiting 4No longer available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Lymphoid 1

Conditions

Multiple Myeloma 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Recurrence 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Renal Insufficiency 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2beta-Thalassemia 1Waldenstrom Macroglobulinemia 1Thalassemia 1Plasmablastic Lymphoma 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Anemia, Sickle Cell 1Amyloidosis 1Acute-Phase Reaction 1

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Bortezomib × Clear all
NCT05519085 2026-05-27

SUCCESSOR-1

Celgene

Phase 3 Recruiting
810 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Shandong New Time Pharmaceutical Co., LTD

Phase 3 Recruiting
261 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT04915248 2025-12-24

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting
28 enrolled
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Recurrence

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Qilu Pharmaceutical Co., Ltd.

Phase 2 Recruiting
160 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡